ENGN
enGene Therapeutics Inc. (NASDAQ)
Healthcare — Biotechnology
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Hold
2.7 / 5
7 analysts
$1.76
+$0.03 (+1.73%)
Target:
$3.29
(86.7%)
Sign in to add ENGN to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $117.90M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.25 |
| EPS (TTM) | $-2.18 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -52.59% |
| Debt/Equity | 13.07 |
| Recommendation | Hold 2.7 |
| Analyst Target | $3.29 |
| Analysts | 7 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 66.0 |
| Beta | -0.29 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $12.25 |
| 52-Week Low | $1.40 |
| 50-Day Avg | $3.15 |
| 200-Day Avg | $6.95 |
| Avg Volume | $1.76M |
| Volume | 605.2K |
Performance Analysis
BULLISHENGN shows predominantly bullish signals based on its fundamentals and technicals.
+
Trading near its 52-week low ($1.40), which could present a value opportunity.
+
RSI at 66.0 shows positive momentum.
-
Price is below both the 50-day and 200-day moving averages — in a downtrend.
~
Wall Street consensus is "Hold" from 7 analysts.
+
Average analyst target of $3.29 implies 86.7% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:07 UTC
Back to Screener Export Report